BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38383563)

  • 21. A comprehensive profile of TCF1
    Wang D; Fang J; Wen S; Li Q; Wang J; Yang L; Dai W; Lu H; Guo J; Shan Z; Xie W; Liu X; Wen L; Shen J; Wang A; Chen Q; Wang Z
    Int J Oral Sci; 2022 Feb; 14(1):8. PubMed ID: 35153298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sharpening up tumor microenvironment to enhance the efficacy of immune checkpoint blockade on head and neck cancer using a CpG-oligodeoxynucleotide.
    Tseng JC; Yang JX; Liu YL; Su YW; Lee AY; Chen YW; Liu KJ; Luo Y; Hong YR; Chuang TH
    Cancer Immunol Immunother; 2022 May; 71(5):1115-1128. PubMed ID: 34581869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
    Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
    Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
    Chen Y; Zheng X; Lin J; Gao X; Xiong J; Liu J; Fei Z; Chen C
    Oral Oncol; 2022 May; 128():105860. PubMed ID: 35428026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
    Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials.
    Dang S; Zhang S; Zhao J; Li X; Li W
    Cancer Med; 2023 Oct; 12(20):20277-20286. PubMed ID: 37814950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
    Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham MP; Lucas P; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy.
    Schoonderwoerd MJA; Koops MFM; Angela RA; Koolmoes B; Toitou M; Paauwe M; Barnhoorn MC; Liu Y; Sier CFM; Hardwick JCH; Nixon AB; Theuer CP; Fransen MF; Hawinkels LJAC
    Clin Cancer Res; 2020 Jul; 26(14):3831-3842. PubMed ID: 32332012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An in silico exploration of combining Interleukin-12 with Oxaliplatin to treat liver-metastatic colorectal cancer.
    Wang Q; Wang Z; Wu Y; Klinke DJ
    BMC Cancer; 2020 Jan; 20(1):26. PubMed ID: 31914948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
    Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
    Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Correlation of the Histoculture Drug Response Assay for Head and Neck Cancer.
    Hoffman RM
    Methods Mol Biol; 2018; 1760():83-92. PubMed ID: 29572796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. γ-Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma.
    Mao L; Zhao ZL; Yu GT; Wu L; Deng WW; Li YC; Liu JF; Bu LL; Liu B; Kulkarni AB; Zhang WF; Zhang L; Sun ZJ
    Int J Cancer; 2018 Mar; 142(5):999-1009. PubMed ID: 29047105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
    Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
    Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
    Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
    Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating CD137
    Cirillo A; Zizzari IG; Botticelli A; Strigari L; Rahimi H; Scagnoli S; Scirocchi F; Pernazza A; Pace A; Cerbelli B; d'Amati G; Marchetti P; Nuti M; Rughetti A; Napoletano C
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
    Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
    Kitsou M; Ayiomamitis GD; Zaravinos A
    Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
    Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
    J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
    Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
    J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.